


(US PIWG)

- Epithelial ovarian, peritoneal, or fallopian carcinoma (EOPFC)
- Stage IIIC-IV and suitable for NACT with interval cytoreductive surgery
- Phase I to evaluate acute toxicity (C1) and cumulative tolerability
- Maintenance ruxolitinib permitted in patients tolerating concurrent therapy
- Primary Endpoints: PFS and molecular targeting (stem cells and IL6)



CP = Carboplatin AUC 5 or 6 (D1), Paclitaxel 80 mg/m² (D1,8,15)

Rux = Ruxolitinib 10-15 mg PO BID (pending Phase 1)

ICS = Interval Cytoreductive Surgery

Open: OCT 2016


Status: Ongoing Accrual (Phase I)

Target: Approximately 150 pts

Notes: Limited to Phase I Working Group with expansion Group-wide

(Group-Wide)

- Epithelial ovarian, peritoneal, or fallopian carcinoma (EOPFC)
- Stage IIIC-IV and suitable for NACT with interval cytoreductive surgery
- No known diabetes or use of metformin
- Primary Endpoints: PFS and molecular/metabolic targeting



CP = Carboplatin AUC 6 (D1), Paclitaxel 80 mg/m² (D1,8,15)

MET = Metformin 850 mg PO BID

ICS = Interval Cytoreductive Surgery

Open: JUN 2014
 Status: Ongoing Accrual (U Chicago SPORE)
 Target: 76 pts
 Notes: Pending Group-wide activation